ArticleScientific reports2018
Development of a characterised tool kit for the interrogation of NLRP3 inflammasome-dependent responses.
Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 31 citations in OpenAlex.
- Molecular Hybridization of Clinically Relevant P2X7 Antagonists.ChemMedChem · 2026Article
- Pulmonary toxicity assessment of polypropylene, polystyrene, and polyethylene microplastic fragments in mice.Toxicological research · 2024Article
- Pyroptosis in bone loss.Apoptosis : an international journal on programmed cell death · 2023Review
- Characterisation of C101248: A novel selective THIK-1 channel inhibitor for the modulation of microglial NLRP3-inflammasome.Neuropharmacology · 2023Article
- Synthesis, biological evaluation and molecular modeling studies of novel 1,2,3-triazole-linked menadione-furan derivatives as P2X7 inhibitors.Journal of bioenergetics and biomembranes · 2022Article
- Spermidine reduces neuroinflammation and soluble amyloid beta in an Alzheimer's disease mouse model.Journal of neuroinflammation · 2022Article
- Loss of NLRP3 increases bacterial cystitis via IRAKM.Translational andrology and urology · 2022Article
- A phenotypic high-content, high-throughput screen identifies inhibitors of NLRP3 inflammasome activation.Scientific reports · 2021Article
- Topical inflammasome inhibition with disulfiram prevents irritant contact dermatitis.Clinical and translational allergy · 2021Article
- Assessing the Association of Mitochondrial Function and Inflammasome Activation in Murine Macrophages Exposed to Select Mitotoxic Tri-Organotin Compounds.Environmental health perspectives · 2021Article
- Selective inhibition of the KChemical science · 2020Article
- Hallmarks of NLRP3 inflammasome activation are observed in organotypic hippocampal slice culture.Immunology · 2020Article
- Discovery ofACS medicinal chemistry letters · 2020Article
- Kefir peptides alleviate particulate matter <4 μm (PMScientific reports · 2019Article
- The three cytokines IL-1β, IL-18, and IL-1α share related but distinct secretory routes.The Journal of biological chemistry · 2019Article
- Article
- Targeting the NLRP3 inflammasome in inflammatory diseases.Nature reviews. Drug discovery · 2018Review
- Rusty Microglia: Trainers of Innate Immunity in Alzheimer's Disease.Frontiers in neurology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 5 institutions in 1 country.
Funding
Abstract
Inflammation is an established contributor to disease and the NLRP3 inflammasome is emerging as a potential therapeutic target. A number of small molecule inhibitors of the NLRP3 pathway have been described. Here we analysed the most promising of these inhibitor classes side by side to assess relative potency and selectivity for their respective putative targets. Assessed using ASC inflammasome-speck formation, and release of IL-1β, in both human monocyte/macrophage THP1 cells and in primary mouse microglia, we compared the relative potency and selectivity of P2X7 inhibitors, inflammasome inhibitors (diarylsulfonylurea vs. the NBC series), and caspase-1 inhibitors. In doing so we are now able to provide a well characterised small molecule tool kit for interrogating and validating inflammasome-dependent responses with a range of nanomolar potency inhibitors against established points in the inflammasome pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.